Equity Long-Short Analyst

Pyari Menon

Pyari has over twenty years of experience in the industry, having worked on both the buy and sell-side including at Goldman Sachs, Credit-Suisse, Deutsche Bank, Intellectual Ventures, Tano Capital, and Franklin Templeton. His coverage has been in technology and midcaps across various geographies including Taiwan, ASEAN, India, the US, and Europe.

Equity Bottom-Up

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)'s</a></strong> Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. </li>
<li>Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.</li>
<li>Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.</li>
</ul>



CVRx (CVRX US)'s Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. 
Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.
Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.


CVRx: Enhancing Cardiac Care Through Neuromodulation